Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12689886,Peak aqueous humor concentrations,"Peak aqueous humor concentrations ranged from 2151 to 7202 ng/ml, half-lives from 76 to 635 hours, and the integral of the area under the concentration-time curve (AUC(0-t)) from 231 to 1911 ng/h per milliliter.",Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12689886/),[ng] / [ml],2151 to 7202,12572,DB00620,Triamcinolone
,12689886,half-lives,"Peak aqueous humor concentrations ranged from 2151 to 7202 ng/ml, half-lives from 76 to 635 hours, and the integral of the area under the concentration-time curve (AUC(0-t)) from 231 to 1911 ng/h per milliliter.",Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12689886/),h,76 to 635,12573,DB00620,Triamcinolone
,12689886,integral of the area under the concentration-time curve (AUC(0-t)),"Peak aqueous humor concentrations ranged from 2151 to 7202 ng/ml, half-lives from 76 to 635 hours, and the integral of the area under the concentration-time curve (AUC(0-t)) from 231 to 1911 ng/h per milliliter.",Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12689886/),[ng] / [h·milliliter],231 to 1911,12574,DB00620,Triamcinolone
,12689886,elimination half-life,"After a single intravitreal injection of triamcinolone, the mean elimination half-life was 18.6 days in nonvitrectomized patients.",Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12689886/),d,18.6,12575,DB00620,Triamcinolone
,12689886,half-life,The half-life in a patient who had undergone a vitrectomy was shorter at 3.2 days.,Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12689886/),d,3.2,12576,DB00620,Triamcinolone
,19089571,elimination half-life,The elimination half-life was 6.08 days for the CP-TA and 5.78 days for the HPP-TA.,Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19089571/),d,6.08,18226,DB00620,Triamcinolone
,19089571,elimination half-life,The elimination half-life was 6.08 days for the CP-TA and 5.78 days for the HPP-TA.,Pharmacokinetic behavior of intravitreal triamcinolone acetonide prepared by a hospital pharmacy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19089571/),d,5.78,18227,DB00620,Triamcinolone
,24868137,half-life,"The half-life of intravitreal injection of 4 mg and 8 mg TA was 24 days and 34 days, respectively.",Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24868137/),d,24,18897,DB00620,Triamcinolone
,24868137,half-life,"The half-life of intravitreal injection of 4 mg and 8 mg TA was 24 days and 34 days, respectively.",Pharmacokinetics and retinal toxicity of various doses of intravitreal triamcinolone acetonide in rabbits. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24868137/),d,34,18898,DB00620,Triamcinolone
,22990317,Particle size,"Particle size (90th percentile) was 47 μm for Kenalog, 26 μm for Triesence, and 22 μm for both compounded preservative-free triamcinolone acetonide and Trivaris.",Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22990317/),μm,47,19116,DB00620,Triamcinolone
,22990317,Particle size,"Particle size (90th percentile) was 47 μm for Kenalog, 26 μm for Triesence, and 22 μm for both compounded preservative-free triamcinolone acetonide and Trivaris.",Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22990317/),μm,26,19117,DB00620,Triamcinolone
,22990317,Particle size,"Particle size (90th percentile) was 47 μm for Kenalog, 26 μm for Triesence, and 22 μm for both compounded preservative-free triamcinolone acetonide and Trivaris.",Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22990317/),μm,22,19118,DB00620,Triamcinolone
,12579879,limit of detection,The limit of detection for pravastatin was 13 ng.,[Determination of pravastatin in rat liver by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579879/),ng,13,20520,DB00620,Triamcinolone
,12579879,signal-to-noise ratio,"mL-1 (signal-to-noise ratio of 3), and the limit of quantification for pravastatin in liver homogenate was 50 ng.g-1 liver (RSD < 20%).",[Determination of pravastatin in rat liver by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579879/),,3,20521,DB00620,Triamcinolone
,12579879,extraction recovery,"The average extraction recovery of pravastatin from liver at different concentrations was 80.8%, and the average inter-day precision was 11%.",[Determination of pravastatin in rat liver by RP-HPLC]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12579879/),%,80.8,20522,DB00620,Triamcinolone
,7131291,ratio,This placental conversion of cortisol to cortisone and the further metabolism and conjugation of cortisol by the fetoplacental unit resulted in a fetal to maternal plasma cortisol ratio of 0.2.,Comparison of the transplacental pharmacokinetics of cortisol and triamcinolone acetonide in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7131291/),,0.2,51824,DB00620,Triamcinolone
,7131291,ratio,"In contrast, the lack of placental or fetoplacental metabolism of TAC resulted in a fetal to maternal plasma TAC ratio of 0.6.",Comparison of the transplacental pharmacokinetics of cortisol and triamcinolone acetonide in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7131291/),,0.6,51825,DB00620,Triamcinolone
,11020028,Peak plasma concentrations,Peak plasma concentrations of pravastatin were found between 60 min and 120 min after oral administration of 60 mg and reached values between 37 microg/l and 126 microg/l.,Determination of pravastatin by high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),[μg] / [l],37,56797,DB00620,Triamcinolone
,11020028,Peak plasma concentrations,Peak plasma concentrations of pravastatin were found between 60 min and 120 min after oral administration of 60 mg and reached values between 37 microg/l and 126 microg/l.,Determination of pravastatin by high performance liquid chromatography. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),[μg] / [l],126,56798,DB00620,Triamcinolone
,11020028,AUCs,The calculated AUCs were between 52 ng/ml x h and 311 ng/ml x h and the corresponding plasma elimination half-life times were between 95 min and 165 min.,Determination of pravastatin by high performance liquid chromatography. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),[ng] / [h·ml],52,56799,DB00620,Triamcinolone
,11020028,AUCs,The calculated AUCs were between 52 ng/ml x h and 311 ng/ml x h and the corresponding plasma elimination half-life times were between 95 min and 165 min.,Determination of pravastatin by high performance liquid chromatography. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),[ng] / [h·ml],311,56800,DB00620,Triamcinolone
,11020028,plasma elimination half-life times,The calculated AUCs were between 52 ng/ml x h and 311 ng/ml x h and the corresponding plasma elimination half-life times were between 95 min and 165 min.,Determination of pravastatin by high performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),min,95,56801,DB00620,Triamcinolone
,11020028,plasma elimination half-life times,The calculated AUCs were between 52 ng/ml x h and 311 ng/ml x h and the corresponding plasma elimination half-life times were between 95 min and 165 min.,Determination of pravastatin by high performance liquid chromatography. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020028/),min,165,56802,DB00620,Triamcinolone
,12532388,concentration determined at steady state,"The concentration determined at steady state in microdialysate, corrected for recovery, was 2.73 +/- 0.42 microg/mL compared to 21.9 +/- 2.3 microg/mL in plasma.",Microdialysis of triamcinolone acetonide in rat muscle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532388/),[μg] / [ml],2.73,59330,DB00620,Triamcinolone
,12532388,concentration determined at steady state,"The concentration determined at steady state in microdialysate, corrected for recovery, was 2.73 +/- 0.42 microg/mL compared to 21.9 +/- 2.3 microg/mL in plasma.",Microdialysis of triamcinolone acetonide in rat muscle. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532388/),[μg] / [ml],21.9,59331,DB00620,Triamcinolone
,12532388,terminal half-life,The pharmacokinetics of TA in plasma was described by an open two-compartment model with a terminal half-life of 2.7 h.,Microdialysis of triamcinolone acetonide in rat muscle. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532388/),h,2.7,59332,DB00620,Triamcinolone
,12532388,clearance,The clearance of TA in rats determined by compartmental analysis was 0.94 L/h/kg.,Microdialysis of triamcinolone acetonide in rat muscle. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532388/),[l] / [h·kg],0.94,59333,DB00620,Triamcinolone
,12532388,Protein binding,"Protein binding in rat plasma, measured by ultrafiltration, was 90.1%.",Microdialysis of triamcinolone acetonide in rat muscle. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12532388/),%,90.1,59334,DB00620,Triamcinolone
,3245858,terminal half-life,"The terminal half-life of 2.7 +/- 1.3 h and tmax of 1.9 +/- 0.5 h are in agreement with corresponding data of other glucocorticoids, whereas the normalized plasma concentration and the volume of distribution are different.",[Pharmacokinetics of triamcinolone following oral administration]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245858/),h,2.7,61576,DB00620,Triamcinolone
,3245858,tmax,"The terminal half-life of 2.7 +/- 1.3 h and tmax of 1.9 +/- 0.5 h are in agreement with corresponding data of other glucocorticoids, whereas the normalized plasma concentration and the volume of distribution are different.",[Pharmacokinetics of triamcinolone following oral administration]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3245858/),h,1.9,61577,DB00620,Triamcinolone
,2396524,rate of uptake,"The normal brain, as demonstrated on isolated cells, revealed a saturable, time-dependent uptake of dexamethasone (rate of uptake, 5 nm/mg protein/min at 37 degrees C).",Pharmacokinetics of glucosteroids in severe head injury. Experimental studies in rat brain after cold lesion. ,Uptake Volume-Q9,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2396524/),[nm] / [·mg·min],5,61779,DB00620,Triamcinolone
,24077088,terminal half-life,The terminal half-life of intravitreal TA was 23.3 days in the vitrectomized eyes and 28.9 days in the nonvitrectomized eyes.,Intravitreal pharmacokinetics after posterior subtenon triamcinolone acetonide injection in vitrectomized rabbit eyes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24077088/),d,23.3,65323,DB00620,Triamcinolone
,24077088,terminal half-life,The terminal half-life of intravitreal TA was 23.3 days in the vitrectomized eyes and 28.9 days in the nonvitrectomized eyes.,Intravitreal pharmacokinetics after posterior subtenon triamcinolone acetonide injection in vitrectomized rabbit eyes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/24077088/),d,28.9,65324,DB00620,Triamcinolone
,1037247,peak of mean concentrations,"3. After application to normal skin or abraded skin, the peak of mean concentrations in the plasma of 220 ng/ml (range 132-276 ng/ml) or 307 ng/ml (range 270-321 ng/ml), respectively, occurred at 24 h.",Absorption and disposition of econazole nitrate after application to the skins and vaginas of rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1037247/),[ng] / [ml],220,70547,DB00620,Triamcinolone
,1037247,peak of mean concentrations,"3. After application to normal skin or abraded skin, the peak of mean concentrations in the plasma of 220 ng/ml (range 132-276 ng/ml) or 307 ng/ml (range 270-321 ng/ml), respectively, occurred at 24 h.",Absorption and disposition of econazole nitrate after application to the skins and vaginas of rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1037247/),[ng] / [ml],307,70548,DB00620,Triamcinolone
,1037247,peak concentration,"5. After vaginal doses of 5 mg, a peak concentration of 209 ng/ml occurred at 6 h in the plasma.",Absorption and disposition of econazole nitrate after application to the skins and vaginas of rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1037247/),[ng] / [ml],209,70549,DB00620,Triamcinolone
,17088419,tmax,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,0.6-1.5,72211,DB00620,Triamcinolone
,17088419,maximum,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),[nM] / [l],2.99-5.51,72212,DB00620,Triamcinolone
,17088419,terminal half-life,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,13.9,72213,DB00620,Triamcinolone
,17088419,terminal half-life,"Kinetic analysis of both the preparations demonstrated rapid absorption (tmax, 0.6-1.5 h) and low maximum plasma concentrations (peak Cmax, 2.99-5.51 nmol/l) of the steroids; indeed, the terminal half-life of TAA-DHP (13.9 +/- 1.3 h) was very much shorter than that of TAA (125.9 +/- 15.8 h).",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,125.9,72214,DB00620,Triamcinolone
,17088419,mean residence time,"In addition, the mean residence time differed very much (11 vs 160 h for TAA-DHP and TAA respectively), in line with a delayed elimination of the depot compared with the long-acting formulation.",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,11,72215,DB00620,Triamcinolone
,17088419,mean residence time,"In addition, the mean residence time differed very much (11 vs 160 h for TAA-DHP and TAA respectively), in line with a delayed elimination of the depot compared with the long-acting formulation.",Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17088419/),h,160,72216,DB00620,Triamcinolone
,26650427,terminal elimination half-life,The terminal elimination half-life of epidural-administered triamcinolone in a noncompartmental analysis was 523 hours.,Serum Triamcinolone Levels Following Interlaminar Epidural Injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650427/),h,523,73979,DB00620,Triamcinolone
,26650427,peak triamcinolone concentrations,"In the noncompartmental analysis, peak triamcinolone concentrations of 4.1 ng/mL were detected within 24 hours after administration.",Serum Triamcinolone Levels Following Interlaminar Epidural Injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26650427/),[ng] / [ml],4.1,73980,DB00620,Triamcinolone
,20678801,concentration peak time,"The TA concentration peak time for aqueous and plasma was at 1 hour and 24 hours, for vitreous after subtenon injection.",Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678801/),h,1,88292,DB00620,Triamcinolone
,20678801,concentration peak time,"The TA concentration peak time for aqueous and plasma was at 1 hour and 24 hours, for vitreous after subtenon injection.",Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678801/),h,24,88293,DB00620,Triamcinolone
,20678801,terminal elimination half-life,"The terminal elimination half-life in aqueous, vitreous, and plasma was 11.8, 17.1, and 25 days, respectively.",Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678801/),d,11.8,88294,DB00620,Triamcinolone
,20678801,terminal elimination half-life,"The terminal elimination half-life in aqueous, vitreous, and plasma was 11.8, 17.1, and 25 days, respectively.",Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678801/),d,17.1,88295,DB00620,Triamcinolone
,20678801,terminal elimination half-life,"The terminal elimination half-life in aqueous, vitreous, and plasma was 11.8, 17.1, and 25 days, respectively.",Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678801/),d,25,88296,DB00620,Triamcinolone
,20678801,area under the concentration time curve (AUC(0-∞)),"The integral of the area under the concentration time curve (AUC(0-∞)) was 862 ng/day/ml for aqueous, 1262 ng/day/ml for vitreous, and 17.4 ng/day/ml for plasma.",Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678801/),[ng] / [d·ml],862,88297,DB00620,Triamcinolone
,20678801,area under the concentration time curve (AUC(0-∞)),"The integral of the area under the concentration time curve (AUC(0-∞)) was 862 ng/day/ml for aqueous, 1262 ng/day/ml for vitreous, and 17.4 ng/day/ml for plasma.",Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678801/),[ng] / [d·ml],1262,88298,DB00620,Triamcinolone
,20678801,area under the concentration time curve (AUC(0-∞)),"The integral of the area under the concentration time curve (AUC(0-∞)) was 862 ng/day/ml for aqueous, 1262 ng/day/ml for vitreous, and 17.4 ng/day/ml for plasma.",Intraocular and systemic pharmacokinetics of triamcinolone acetonide after a single 40-mg posterior subtenon application. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20678801/),[ng] / [d·ml],17.4,88299,DB00620,Triamcinolone
under,29550043,run time,The run time is under 5 minutes.,Simultaneous determination of triamcinolone hexacetonide and triamcinolone acetonide in rabbit plasma using a highly sensitive and selective UPLC-MS/MS method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29550043/),min,5,90226,DB00620,Triamcinolone
,23331052,half-life,"Rabbit PK data demonstrated that following a single 1,280 μg IVT injection resulted in sustained DXM levels in the retina and choroid (1,179.6 and 577.7 ng/g with a half-life of 189 and 103 days, respectively) sufficient to inhibit VEGF-induced vascular hyper-permeability for up to 9 months.",A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331052/),d,189,92643,DB00620,Triamcinolone
,23331052,half-life,"Rabbit PK data demonstrated that following a single 1,280 μg IVT injection resulted in sustained DXM levels in the retina and choroid (1,179.6 and 577.7 ng/g with a half-life of 189 and 103 days, respectively) sufficient to inhibit VEGF-induced vascular hyper-permeability for up to 9 months.",A preliminary evaluation of dexamethasone palmitate emulsion: a novel intravitreal sustained delivery of corticosteroid for treatment of macular edema. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23331052/),d,103,92644,DB00620,Triamcinolone
,8549229,half-life,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),h,1.150,98700,DB00620,Triamcinolone
,8549229,excretion constant,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ke] / [h],0.686,98701,DB00620,Triamcinolone
,8549229,volume of distribution,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [kg],607,98702,DB00620,Triamcinolone
,8549229,clearance rate,"The pharmacokinetic parameters tested and their means were a half-life of 1.150 +/- 0.233 (+/- SEM) hours, an excretion constant of 0.686 +/- 0.018 Ke/hr, a volume of distribution of 607 +/- 109 ml/kg, and a clearance rate of 374 +/- 47 ml/hr/kg.",Pharmacokinetics of intravenously administration of prednisolone in the horse as determined by radioimmunoassay. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8549229/),[ml] / [h·kg],374,98703,DB00620,Triamcinolone
,25497892,flow rate,"After simple liquid-liquid extraction, the analytes and internal standard (dexamethasone, DEX) were separated on Phenomenex Luna C18 column (50 mm × 2.1mm, 1.7 μm) using a mobile phase consisting of solvent A (acetonitrile) and solvent B (0.1% ammonia solution) at a flow rate of 0.2 ml/min with gradient elution.",Simultaneous determination of triamcinolone acetonide palmitate and triamcinolone acetonide in beagle dog plasma by UPLC-MS/MS and its application to a long-term pharmacokinetic study of triamcinolone acetonide palmitate lipid emulsion injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25497892/),[ml] / [min],0.2,107021,DB00620,Triamcinolone
,25497892,recoveries,"The mean recoveries of TAP, TA and IS were 86.7-104.7%.",Simultaneous determination of triamcinolone acetonide palmitate and triamcinolone acetonide in beagle dog plasma by UPLC-MS/MS and its application to a long-term pharmacokinetic study of triamcinolone acetonide palmitate lipid emulsion injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25497892/),%,86.7-104.7,107022,DB00620,Triamcinolone
<,17031285,unbound VEGF concentration,"In Patient 1, the unbound bevacizumab level was 0.16% of the loading dose (or 500,000 pg/mL) and the unbound VEGF concentration was <41 pg/mL 4 weeks after the bevacizumab injection.",Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17031285/),[pg] / [ml],41,109272,DB00620,Triamcinolone
<,17031285,unbound VEGF level,"In Patient 2, the unbound bevacizumab level was 53% of the loading dose (or 166,000,000 pg/mL) at 48 hours, with an unbound VEGF level of <41 pg/mL.",Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17031285/),[pg] / [ml],41,109273,DB00620,Triamcinolone
,17031285,half-life,"A single dose of intravitreal bevacizumab is likely to provide complete intravitreal VEGF blockade for a minimum of 4 weeks, with an intravitreal bevacizumab half-life of approximately 3 days.",Vitreous levels of unbound bevacizumab and unbound vascular endothelial growth factor in two patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17031285/),d,3,109274,DB00620,Triamcinolone
,16077349,half-life,The half-life of triamcinolone acetonide was 1.57 days in the vitrectomized group and 2.89 days in the nonvitrectomized group.,Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16077349/),d,1.57,112411,DB00620,Triamcinolone
,16077349,half-life,The half-life of triamcinolone acetonide was 1.57 days in the vitrectomized group and 2.89 days in the nonvitrectomized group.,Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16077349/),d,2.89,112412,DB00620,Triamcinolone
,3207561,renal clearance,2. The mean (+/- s.e. mean) renal clearance of sulphadimidine was increased from 0.03 +/- 0.01 to 0.07 +/- 0.02 ml min-1 kg-1 (P = 0.01) following the administration of intra-articular steroid.,Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207561/),[ml] / [kg·min],0.03,115005,DB00620,Triamcinolone
,3207561,renal clearance,2. The mean (+/- s.e. mean) renal clearance of sulphadimidine was increased from 0.03 +/- 0.01 to 0.07 +/- 0.02 ml min-1 kg-1 (P = 0.01) following the administration of intra-articular steroid.,Effect of intra-articular glucocorticoids on the disposition of sulphadimidine in chronic osteoarthritis patients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3207561/),[ml] / [kg·min],0.07,115006,DB00620,Triamcinolone
,4051860,half-life,"The half-life as determined by HPLC was 1.6 days, the level at 13 days postinjection was 66 +/- 19 micrograms, and no drug was detectable by HPLC analysis at 21 days in five of six eyes.",Clearance of triamcinolone from vitreous. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4051860/),d,1.6,121703,DB00620,Triamcinolone
,4051860,half-life,"The half-life as determined by HPLC was 1.6 days, the level at 13 days postinjection was 66 +/- 19 micrograms, and no drug was detectable by HPLC analysis at 21 days in five of six eyes.",Clearance of triamcinolone from vitreous. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4051860/),μg,66,121704,DB00620,Triamcinolone
,11855992,half-life,Kinetic analysis of the hydrolysis rate demonstrated that the conjugate had a half-life of 23.6 h in aqueous solutions.,"Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855992/),h,23.6,123174,DB00620,Triamcinolone
,11855992,IC(50),"The antiproliferative activities of the MMC-TA conjugate and MMC were both concentration dependent, with similar IC(50) values of 2.4 and 1.7 microM, respectively.","Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855992/),μM,2.4,123175,DB00620,Triamcinolone
,11855992,IC(50),"The antiproliferative activities of the MMC-TA conjugate and MMC were both concentration dependent, with similar IC(50) values of 2.4 and 1.7 microM, respectively.","Synthesis, pharmacokinetics, efficacy, and rat retinal toxicity of a novel mitomycin C-triamcinolone acetonide conjugate. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11855992/),μM,1.7,123176,DB00620,Triamcinolone
,16428920,AUCinf,"However, for the higher dose strength, plasma exposure was higher with the Ultrahaler formulation as compared with the MDI formulation (mean AUCinf DPI/MDI ratios: 1.96).","Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428920/),,1.96,124197,DB00620,Triamcinolone
,16428920,ratios,"However, for the higher dose strength, plasma exposure was higher with the Ultrahaler formulation as compared with the MDI formulation (mean AUCinf DPI/MDI ratios: 1.96).","Development of a dry powder inhaler, the Ultrahaler, containing triamcinolone acetonide using in vitro-in vivo relationships. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16428920/),,1.96,124198,DB00620,Triamcinolone
,23574452,Maximum measured plasma TA concentrations,"Maximum measured plasma TA concentrations were 0.996 ± 0.391 at 13.2 h and 1.27 ± 0.278 ng/ml at 6.5 h for i.m. and intra-articular administration, respectively.",Pharmacokinetics of triamcinolone acetonide following intramuscular and intra-articular administration to exercised Thoroughbred horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23574452/),,0.996,126856,DB00620,Triamcinolone
,23574452,Maximum measured plasma TA concentrations,"Maximum measured plasma TA concentrations were 0.996 ± 0.391 at 13.2 h and 1.27 ± 0.278 ng/ml at 6.5 h for i.m. and intra-articular administration, respectively.",Pharmacokinetics of triamcinolone acetonide following intramuscular and intra-articular administration to exercised Thoroughbred horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23574452/),[ng] / [ml],1.27,126857,DB00620,Triamcinolone
,23574452,plasma terminal elimination half-life,"The plasma terminal elimination half-life was 11.4 ± 6.53 and 0.78 ± 1.00 days for i.m. and intra-articular administration, respectively.",Pharmacokinetics of triamcinolone acetonide following intramuscular and intra-articular administration to exercised Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23574452/),d,11.4,126858,DB00620,Triamcinolone
,23574452,plasma terminal elimination half-life,"The plasma terminal elimination half-life was 11.4 ± 6.53 and 0.78 ± 1.00 days for i.m. and intra-articular administration, respectively.",Pharmacokinetics of triamcinolone acetonide following intramuscular and intra-articular administration to exercised Thoroughbred horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23574452/),d,0.78,126859,DB00620,Triamcinolone
,24122883,serum clearance,"Canakinumab has low serum clearance (0.214 L/day), low steady-state volume of distribution (7.44 L), a 25.8-day half-life, and approximately 60% subcutaneous absolute bioavailability in a typical 93-kg patient.",Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122883/),[l] / [d],0.214,129473,DB00620,Triamcinolone
,24122883,steady-state volume of distribution,"Canakinumab has low serum clearance (0.214 L/day), low steady-state volume of distribution (7.44 L), a 25.8-day half-life, and approximately 60% subcutaneous absolute bioavailability in a typical 93-kg patient.",Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122883/),l,7.44,129474,DB00620,Triamcinolone
,24122883,half-life,"Canakinumab has low serum clearance (0.214 L/day), low steady-state volume of distribution (7.44 L), a 25.8-day half-life, and approximately 60% subcutaneous absolute bioavailability in a typical 93-kg patient.",Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122883/),d,25.8,129475,DB00620,Triamcinolone
,24122883,subcutaneous absolute bioavailability,"Canakinumab has low serum clearance (0.214 L/day), low steady-state volume of distribution (7.44 L), a 25.8-day half-life, and approximately 60% subcutaneous absolute bioavailability in a typical 93-kg patient.",Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122883/),%,60,129476,DB00620,Triamcinolone
,24122883,apparent in vivo dissociation constant,"Total IL-1β kinetics and canakinumab pharmacokinetics were characterized by a population-based pharmacokinetic-binding model, where the estimated apparent in vivo dissociation constant (signifying binding affinity of canakinumab to circulating IL-1β) was 0.99 nmol/L in gouty arthritis patients.",Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24122883/),[nM] / [l],0.99,129477,DB00620,Triamcinolone
,22679829,flow rate,"The isocratic elution of methanol and 0.1% (v/v) formic acid aqueous solution as mobile phase was performed at a flow rate of 0.2 mL/min, and a rapid separation was completed within 3 min.",[Determination of mitomycin C in rabbit plasma by ultra-high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22679829/),[ml] / [min],0.2,130335,DB00620,Triamcinolone
,22679829,m/,The monitoring ions of MMC and IS were m/z 335.,[Determination of mitomycin C in rabbit plasma by ultra-high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22679829/),,335,130336,DB00620,Triamcinolone
,22679829,m/z,2 --> 242.2 and m/z 435.2 --> 397.,[Determination of mitomycin C in rabbit plasma by ultra-high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22679829/),,435.2,130337,DB00620,Triamcinolone
,22679829,m/z,2 --> 242.2 and m/z 435.2 --> 397.,[Determination of mitomycin C in rabbit plasma by ultra-high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22679829/),,397,130338,DB00620,Triamcinolone
,22679829,limit of detection (S/N,The limit of detection (S/N = 3) was 0.2 microg/L.,[Determination of mitomycin C in rabbit plasma by ultra-high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22679829/),[μg] / [l],3,130339,DB00620,Triamcinolone
,22679829,limit of detection (S/N,The limit of detection (S/N = 3) was 0.2 microg/L.,[Determination of mitomycin C in rabbit plasma by ultra-high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22679829/),[μg] / [l],0.2,130340,DB00620,Triamcinolone
,22679829,recoveries,"The recoveries were from 85% to 115% at the spiked levels of 1, 5, 100 and 800 microg/L, and the relative standard deviations (RSDs) of intra- and inter-day were both less than 15%.",[Determination of mitomycin C in rabbit plasma by ultra-high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22679829/),%,85,130341,DB00620,Triamcinolone
,22679829,recoveries,"The recoveries were from 85% to 115% at the spiked levels of 1, 5, 100 and 800 microg/L, and the relative standard deviations (RSDs) of intra- and inter-day were both less than 15%.",[Determination of mitomycin C in rabbit plasma by ultra-high performance liquid chromatography-tandem mass spectrometry]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22679829/),%,115,130342,DB00620,Triamcinolone
,18357737,flow-rate,"Chromatographic separation was performed on a Capcell Pak C18 MG column with the mobile phase consisted of acetonitrile -5 mmol x L(-1) ammonium acetate (60:40, v/v) at a flow-rate of 0.50 mL x min(-1).",[LC-MS/MS determination of budesonide in dog plasma]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18357737/),[ml] / [min],0.50,139304,DB00620,Triamcinolone
,18357737,Cmax,"Maximal budesonide plasma level was observed after (3.5 +/- 3.3) h and the Cmax was (786 +/- 498) pg x mL(-1) after a single oral administration of 9 mg budesonide capsules, Cmax was increased to (2142 +/- 1515) pg x mL(-1) after multiple oral administration (9 mg x 5 d) of budesonide capsules.",[LC-MS/MS determination of budesonide in dog plasma]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18357737/),[pg] / [ml],786,139305,DB00620,Triamcinolone
,18357737,Cmax,"Maximal budesonide plasma level was observed after (3.5 +/- 3.3) h and the Cmax was (786 +/- 498) pg x mL(-1) after a single oral administration of 9 mg budesonide capsules, Cmax was increased to (2142 +/- 1515) pg x mL(-1) after multiple oral administration (9 mg x 5 d) of budesonide capsules.",[LC-MS/MS determination of budesonide in dog plasma]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18357737/),[pg] / [ml],2142,139306,DB00620,Triamcinolone
,31662801,Peak plasma triamcinolone acetonide concentrations (Cmax),"Peak plasma triamcinolone acetonide concentrations (Cmax) were lower following bilateral TA-ER injections [geometric mean, 2277.7 pg/ml (95% CI, 1602.13-3238.04)] compared with bilateral TAcs injections [7394.7 pg/ml (2201.06-24,843.43)], with median times to Cmax (Tmax) of 4.5 and 6.5 h, respectively.","A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662801/),[pg] / [ml],2277.7,142535,DB00620,Triamcinolone
,31662801,Peak plasma triamcinolone acetonide concentrations (Cmax),"Peak plasma triamcinolone acetonide concentrations (Cmax) were lower following bilateral TA-ER injections [geometric mean, 2277.7 pg/ml (95% CI, 1602.13-3238.04)] compared with bilateral TAcs injections [7394.7 pg/ml (2201.06-24,843.43)], with median times to Cmax (Tmax) of 4.5 and 6.5 h, respectively.","A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662801/),[pg] / [ml],7394.7,142536,DB00620,Triamcinolone
,31662801,times to Cmax (Tmax),"Peak plasma triamcinolone acetonide concentrations (Cmax) were lower following bilateral TA-ER injections [geometric mean, 2277.7 pg/ml (95% CI, 1602.13-3238.04)] compared with bilateral TAcs injections [7394.7 pg/ml (2201.06-24,843.43)], with median times to Cmax (Tmax) of 4.5 and 6.5 h, respectively.","A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662801/),h,4.5,142537,DB00620,Triamcinolone
,31662801,times to Cmax (Tmax),"Peak plasma triamcinolone acetonide concentrations (Cmax) were lower following bilateral TA-ER injections [geometric mean, 2277.7 pg/ml (95% CI, 1602.13-3238.04)] compared with bilateral TAcs injections [7394.7 pg/ml (2201.06-24,843.43)], with median times to Cmax (Tmax) of 4.5 and 6.5 h, respectively.","A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31662801/),h,6.5,142538,DB00620,Triamcinolone
,29436106,terminal elimination half-life,The terminal elimination half-life of triamcinolone in a noncompartmental analysis was 213 hours.,Corticosteroid and Cortisol Serum Levels Following Intra-articular Triamcinolone Acetonide Lumbar Facet Joint Injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436106/),h,213,142926,DB00620,Triamcinolone
,29436106,peak median triamcinolone concentration,The peak median triamcinolone concentration of 3.6 ng/mL was detected within 24 hours after the injections.,Corticosteroid and Cortisol Serum Levels Following Intra-articular Triamcinolone Acetonide Lumbar Facet Joint Injections. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436106/),[ng] / [ml],3.6,142927,DB00620,Triamcinolone
,29436106,terminal elimination half-life,"The median terminal elimination half-life was 213 hours, but baseline cortisol levels were suppressed for an average of 4.4 days.",Corticosteroid and Cortisol Serum Levels Following Intra-articular Triamcinolone Acetonide Lumbar Facet Joint Injections. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29436106/),h,213,142928,DB00620,Triamcinolone
,10392324,absolute bioavailability,The mean (+/- SD) absolute bioavailability value for inhaled triamcinolone acetonide was 25% (8.75%).,A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392324/),%,25,145572,DB00620,Triamcinolone
,10392324,total body clearance,Mean (+/- SD) total body clearance was rapid at 0.57 (0.12) L/hr/kg.,A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392324/),[l] / [h·kg],0.57,145573,DB00620,Triamcinolone
,10392324,apparent volume of distribution,The mean (+/- SD) apparent volume of distribution following the intravenous dose was a low 1.96 (0.31) L/kg.,A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392324/),[l] / [kg],1.96,145574,DB00620,Triamcinolone
,10392324,apparent terminal elimination half-life,No significant differences were noted in the apparent terminal elimination half-life of triamcinolone acetonide (approximately 2.4 hr) between treatments.,A pharmacokinetic study to evaluate the absolute bioavailability of triamcinolone acetonide following inhalation administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10392324/),h,2.4,145575,DB00620,Triamcinolone
,10667036,terminal half-life,"Based on plasma TCA concentrations in our patient, we calculated a terminal half-life of TCA of 33 days as opposed to 5 days observed after intra-articular administration of a therapeutic dose of 40 mg TCA.",Clinical and pharmacological aspects of accidental triamcinolone acetonide overdosage: a case study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10667036/),d,33,146035,DB00620,Triamcinolone
,10667036,terminal half-life,"Based on plasma TCA concentrations in our patient, we calculated a terminal half-life of TCA of 33 days as opposed to 5 days observed after intra-articular administration of a therapeutic dose of 40 mg TCA.",Clinical and pharmacological aspects of accidental triamcinolone acetonide overdosage: a case study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10667036/),d,5,146036,DB00620,Triamcinolone
,7608322,total body clearance,"After intravenous administration, triamcinolone acetonide was eliminated with a total body clearance of 37 L/h and a half-life of 2.0 hours.","Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608322/),[l] / [h],37,150898,DB00620,Triamcinolone
,7608322,half-life,"After intravenous administration, triamcinolone acetonide was eliminated with a total body clearance of 37 L/h and a half-life of 2.0 hours.","Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608322/),h,2.0,150899,DB00620,Triamcinolone
,7608322,volume of distribution,"The volume of distribution was 103 L, and oral bioavailability averaged 23%.","Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608322/),l,103,150900,DB00620,Triamcinolone
,7608322,oral bioavailability,"The volume of distribution was 103 L, and oral bioavailability averaged 23%.","Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608322/),%,23,150901,DB00620,Triamcinolone
,7608322,maximum triamcinolone acetonide levels,"Absorption was rapid, achieving maximum triamcinolone acetonide levels of 10.5 ng/mL after 1 hour.","Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608322/),[ng] / [ml],10.5,150902,DB00620,Triamcinolone
,7608322,bioavailability,"After inhalation, bioavailability averaged 22% with maximum levels of 2.0 ng/mL observed after 2.1 hours.","Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608322/),%,22,150903,DB00620,Triamcinolone
,7608322,maximum levels,"After inhalation, bioavailability averaged 22% with maximum levels of 2.0 ng/mL observed after 2.1 hours.","Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7608322/),[ng] / [ml],2.0,150904,DB00620,Triamcinolone
,8750370,free fraction,"The free fraction of TCA (+/- standard deviation) was 29.0 +/- 1.3% and was independent of the investigated concentration range up to 1,000 ng/mL.","Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8750370/),%,29.0,152394,DB00620,Triamcinolone
,16770258,half-lives,"The half-lives of the injection amount in the vitreous, 4-mg TA-PF, 16-mg TA-PF, and 4-mg Kenalog, were found to be 24 days, 39 days, and 23 days, respectively.",Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770258/),d,24,154583,DB00620,Triamcinolone
,16770258,half-lives,"The half-lives of the injection amount in the vitreous, 4-mg TA-PF, 16-mg TA-PF, and 4-mg Kenalog, were found to be 24 days, 39 days, and 23 days, respectively.",Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770258/),d,39,154584,DB00620,Triamcinolone
,16770258,half-lives,"The half-lives of the injection amount in the vitreous, 4-mg TA-PF, 16-mg TA-PF, and 4-mg Kenalog, were found to be 24 days, 39 days, and 23 days, respectively.",Safety and pharmacokinetics of a preservative-free triamcinolone acetonide formulation for intravitreal administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16770258/),d,23,154585,DB00620,Triamcinolone
,31744668,flow rate,"Using testosterone as internal standard, the plasma samples were prepared by precipitation with acetonitrile and separated using an ACQUITY UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) with a mobile phase composed of acetonitrile and 0.1 % (v/v) formic acid aqueous solution by gradient elution at a flow rate of 0.3 mL/min.",Development and validation of a LC-MS/MS method for simultaneous determination of six glucocorticoids and its application to a pharmacokinetic study in nude mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31744668/),[ml] / [min],0.3,155222,DB00620,Triamcinolone
,29024802,T,"SF TA concentrations following FX006 were quantifiable through Week 12 (pg/mL: 231,328.9 at Week 1; 3590.0 at Week 6; 290.6 at Week 12); post-TAcs, only two of eight patients had quantifiable SF TA at Week 6 (7.7 pg/mL).",Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29024802/),[pg] / [ml],"231,328.9",157719,DB00620,Triamcinolone
,29024802,T,"SF TA concentrations following FX006 were quantifiable through Week 12 (pg/mL: 231,328.9 at Week 1; 3590.0 at Week 6; 290.6 at Week 12); post-TAcs, only two of eight patients had quantifiable SF TA at Week 6 (7.7 pg/mL).",Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29024802/),[pg] / [ml],3590.0,157720,DB00620,Triamcinolone
,29024802,T,"SF TA concentrations following FX006 were quantifiable through Week 12 (pg/mL: 231,328.9 at Week 1; 3590.0 at Week 6; 290.6 at Week 12); post-TAcs, only two of eight patients had quantifiable SF TA at Week 6 (7.7 pg/mL).",Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29024802/),[pg] / [ml],290,157721,DB00620,Triamcinolone
,29024802,TA,"SF TA concentrations following FX006 were quantifiable through Week 12 (pg/mL: 231,328.9 at Week 1; 3590.0 at Week 6; 290.6 at Week 12); post-TAcs, only two of eight patients had quantifiable SF TA at Week 6 (7.7 pg/mL).",Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29024802/),[pg] / [ml],7.7,157722,DB00620,Triamcinolone
,29155490,peak urinary T concentration,"The peak urinary T concentration was 3211.4 ± 860.3 ng/mL (mean ± SD), time to peak concentration was 1.7 ± 0.9 hours, and the estimated elimination half-life was 4.4 ± 2.8 hours.",Elimination profile of triamcinolone in urine following oral administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29155490/),[ng] / [ml],3211.4,168881,DB00620,Triamcinolone
,29155490,time to peak concentration,"The peak urinary T concentration was 3211.4 ± 860.3 ng/mL (mean ± SD), time to peak concentration was 1.7 ± 0.9 hours, and the estimated elimination half-life was 4.4 ± 2.8 hours.",Elimination profile of triamcinolone in urine following oral administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29155490/),h,1.7,168882,DB00620,Triamcinolone
,29155490,elimination half-life,"The peak urinary T concentration was 3211.4 ± 860.3 ng/mL (mean ± SD), time to peak concentration was 1.7 ± 0.9 hours, and the estimated elimination half-life was 4.4 ± 2.8 hours.",Elimination profile of triamcinolone in urine following oral administration. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29155490/),h,4.4,168883,DB00620,Triamcinolone
,29755622,terminal elimination half-life,The terminal elimination half-life of cervical epidural-administered triamcinolone in a noncompartmental analysis was 219 hours.,Serum Triamcinolone Levels following Cervical Interlaminar Epidural Injection. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755622/),h,219,176631,DB00620,Triamcinolone
,29755622,peak triamcinolone concentrations,"In the noncompartmental analysis, peak triamcinolone concentrations of 5.4 ng/mL were detected within 22.1 hours after administration.",Serum Triamcinolone Levels following Cervical Interlaminar Epidural Injection. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755622/),[ng] / [ml],5.4,176632,DB00620,Triamcinolone
,9653968,recovery,The recovery of pravastatin from plasma was 69.2+/-6.7% (mean+/-S.D.).,Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653968/),%,69.2,197857,DB00620,Triamcinolone
,9653968,limit of detection,"The limit of detection for pravastatin in aqueous solution was 0.4 ng, the limit of quantitation in plasma was 2 ng/ml.",Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653968/),ng,0.4,197858,DB00620,Triamcinolone
,9653968,t1/2,In a preliminary pharmacokinetic study with two healthy volunteers the t1/2 of pravastatin in plasma was found to be 0.8 and 2.3 h.,Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653968/),h,0.8,197859,DB00620,Triamcinolone
,9653968,t1/2,In a preliminary pharmacokinetic study with two healthy volunteers the t1/2 of pravastatin in plasma was found to be 0.8 and 2.3 h.,Determination of pravastatin in human plasma by high-performance liquid chromatography with ultraviolet detection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653968/),h,2.3,197860,DB00620,Triamcinolone
,807712,t1/2,"The radioactivity was eliminated rapidly (t1/2 = 1-2 hr) from plasma (dogs, monkeys, and rats) and tissues (rats) after intramuscular or intravenous administration.","Metabolism of triamcinolone acetonide-21-phosphate in dogs, monkeys, and rats. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/807712/),h,1-2,201843,DB00620,Triamcinolone
,1919393,PCR,The osteocalcin PCR was reduced significantly in UOX compared with OX sheep (2.0 +/- 0.1 (n = 9) vs 2.5 +/- 0.1 litres/h (n = 44); P less than 0.0005).,The effect of uninephrectomy on osteocalcin metabolism in sheep: a direct evaluation of renal osteocalcin clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919393/),[l] / [h],2.0,204276,DB00620,Triamcinolone
,1919393,PCR,The osteocalcin PCR was reduced significantly in UOX compared with OX sheep (2.0 +/- 0.1 (n = 9) vs 2.5 +/- 0.1 litres/h (n = 44); P less than 0.0005).,The effect of uninephrectomy on osteocalcin metabolism in sheep: a direct evaluation of renal osteocalcin clearance. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1919393/),[l] / [h],2.5,204277,DB00620,Triamcinolone
,19450879,half-life,The TA was cleared from the aqueous in a monoexponential manner with a half-life of 29.6 days and clearance coefficient of 0.0234 (1/day).,Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19450879/),d,29.6,204873,DB00620,Triamcinolone
,19450879,clearance coefficient,The TA was cleared from the aqueous in a monoexponential manner with a half-life of 29.6 days and clearance coefficient of 0.0234 (1/day).,Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19450879/),[1] / [d],0.0234,204874,DB00620,Triamcinolone
,19450879,maximum TA concentration,"The extrapolated maximum TA concentration in aqueous was about 3312 ng/ml and the area under the curve was 74,017 day x ng/ml.",Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19450879/),[ng] / [ml],3312,204875,DB00620,Triamcinolone
,19450879,area under the curve,"The extrapolated maximum TA concentration in aqueous was about 3312 ng/ml and the area under the curve was 74,017 day x ng/ml.",Triamcinolone acetonide concentration of aqueous humor after decanted 20-mg intravitreal injection. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19450879/),[d·ng] / [ml],"74,017",204876,DB00620,Triamcinolone
,1587965,half-life,The pharmacokinetic profiles that were obtained showed slow and limited absorption over the first 4 hours after dosing followed by rapid elimination with a half-life of approximately 2 hours (range: 1.8-2.3 hr).,Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587965/),h,2,210743,DB00620,Triamcinolone
,1587965,Cmax,"Mean Cmax values ranged from 0.51 ng/mL after the 400 mcg dose to 1.01 ng/mL and 1.97 ng/mL after the 800 and 1600 mcg doses, respectively.",Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587965/),[ng] / [ml],0.51,210744,DB00620,Triamcinolone
,1587965,Cmax,"Mean Cmax values ranged from 0.51 ng/mL after the 400 mcg dose to 1.01 ng/mL and 1.97 ng/mL after the 800 and 1600 mcg doses, respectively.",Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587965/),[ng] / [ml],1.01,210745,DB00620,Triamcinolone
,1587965,Cmax,"Mean Cmax values ranged from 0.51 ng/mL after the 400 mcg dose to 1.01 ng/mL and 1.97 ng/mL after the 800 and 1600 mcg doses, respectively.",Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587965/),[ng] / [ml],1.97,210746,DB00620,Triamcinolone
,1587965,AUC0-10,"Mean AUC0-10 values for these same doses were 2.6 ng x hr/mL, 5.3 ng x hr/mL and 10.5 ng x hr/mL, respectively.",Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587965/),[h·ng] / [ml],2.6,210747,DB00620,Triamcinolone
,1587965,AUC0-10,"Mean AUC0-10 values for these same doses were 2.6 ng x hr/mL, 5.3 ng x hr/mL and 10.5 ng x hr/mL, respectively.",Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587965/),[h·ng] / [ml],5.3,210748,DB00620,Triamcinolone
,1587965,AUC0-10,"Mean AUC0-10 values for these same doses were 2.6 ng x hr/mL, 5.3 ng x hr/mL and 10.5 ng x hr/mL, respectively.",Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1587965/),[h·ng] / [ml],10.5,210749,DB00620,Triamcinolone
,21879982,distribution half-life,"Median distribution half-life was 0.50 hours (range, 0.24 to 0.67 hours); elimination half-life was 6.1 hours (range, 5.0 to 6.4 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,0.50,215233,DB00620,Triamcinolone
,21879982,elimination half-life,"Median distribution half-life was 0.50 hours (range, 0.24 to 0.67 hours); elimination half-life was 6.1 hours (range, 5.0 to 6.4 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,6.1,215234,DB00620,Triamcinolone
,21879982,Transfer half-life,"Transfer half-life of TA from joint to plasma was 5.2 hours (range, 0.49 to 73 hours); elimination half-life was 23.8 hours (range, 18.9 to 32.2 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,5.2,215235,DB00620,Triamcinolone
,21879982,elimination half-life,"Transfer half-life of TA from joint to plasma was 5.2 hours (range, 0.49 to 73 hours); elimination half-life was 23.8 hours (range, 18.9 to 32.2 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),h,23.8,215236,DB00620,Triamcinolone
,21879982,Maximum plasma concentration,"Maximum plasma concentration following i.a. administration was 2.0 ng/mL (range, 0.94 to 2.5 ng/mL), and was attained at 10 hours (range, 8 to 12 hours).","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),[ng] / [ml],2.0,215237,DB00620,Triamcinolone
,21879982,Maximum plasma concentration,"Maximum plasma concentration following i.m. administration was 0.34 ng/mL (range, 0.20 to 0.48 ng/mL) and was attained at 13.0 hours (range, 12 to 16 hours); concentration was still quantifiable at 360 hours.","Pharmacokinetics of intra-articular, intravenous, and intramuscular administration of triamcinolone acetonide and its effect on endogenous plasma hydrocortisone and cortisone concentrations in horses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21879982/),[ng] / [ml],0.34,215238,DB00620,Triamcinolone
,15452046,half-life,"The mean estimated half-life of triamcinolone +/- SD was 15.4 +/- 1.9 days, and the mean maximum duration of its effect (+/-SD), 140 +/- 17 days.",Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15452046/),d,15.4,218443,DB00620,Triamcinolone
,15452046,maximum duration of its effect,"The mean estimated half-life of triamcinolone +/- SD was 15.4 +/- 1.9 days, and the mean maximum duration of its effect (+/-SD), 140 +/- 17 days.",Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15452046/),d,140,218444,DB00620,Triamcinolone
,6879456,plasma elimination half-life,"The plasma elimination half-life for TAC, 86 min, was also calculated to be significantly longer than that for cortisol, 8 min.",Comparative distribution and metabolism of triamcinolone acetonide and cortisol in the rat embryomaternal unit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879456/),min,86,220221,DB00620,Triamcinolone
,6879456,plasma elimination half-life,"The plasma elimination half-life for TAC, 86 min, was also calculated to be significantly longer than that for cortisol, 8 min.",Comparative distribution and metabolism of triamcinolone acetonide and cortisol in the rat embryomaternal unit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879456/),min,8,220222,DB00620,Triamcinolone
,6879456,elimination half-life,The elimination half-life for unchanged TAC in the embryos was 142 min compared to 22 min for cortisol.,Comparative distribution and metabolism of triamcinolone acetonide and cortisol in the rat embryomaternal unit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879456/),min,142,220223,DB00620,Triamcinolone
,6879456,elimination half-life,The elimination half-life for unchanged TAC in the embryos was 142 min compared to 22 min for cortisol.,Comparative distribution and metabolism of triamcinolone acetonide and cortisol in the rat embryomaternal unit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/6879456/),min,22,220224,DB00620,Triamcinolone
,20884303,overall recovery,"An efficient solid-phase extraction (SPE) procedure for plasma samples yielded extremely clean extracts with overall recovery of 104.3% and 95.7% for triamcinolone acetonide (TA) and fluticasone propionate, respectively.",Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20884303/),%,104.3,221211,DB00620,Triamcinolone
,20884303,overall recovery,"An efficient solid-phase extraction (SPE) procedure for plasma samples yielded extremely clean extracts with overall recovery of 104.3% and 95.7% for triamcinolone acetonide (TA) and fluticasone propionate, respectively.",Simultaneous HPLC analysis of triamcinolone acetonide and budesonide in microdialysate and rat plasma: application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20884303/),%,95.7,221212,DB00620,Triamcinolone
,18503001,permeability constant for the transscleral diffusion (K(trans)),The permeability constant for the transscleral diffusion (K(trans)) of OGTA was 1.12 x 10(-7) +/- 0.08 cm/s (n = 8) during the steady state perfusion.,Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503001/),[cm] / [s],1.12 x 10(-7),222198,DB00620,Triamcinolone
,18503001,maximum OGTA concentration,The maximum OGTA concentration in the retina/choroid after subtenon injection was 25.77 +/- 10.26 ng/mL in the live rabbit at 3 hours and 84.68 +/- 21.04 ng/mL in the euthanatized rabbits at 8 hours.,Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503001/),[ng] / [ml],25.77,222199,DB00620,Triamcinolone
,18503001,maximum OGTA concentration,The maximum OGTA concentration in the retina/choroid after subtenon injection was 25.77 +/- 10.26 ng/mL in the live rabbit at 3 hours and 84.68 +/- 21.04 ng/mL in the euthanatized rabbits at 8 hours.,Pharmacokinetics of intraocular drug delivery of Oregon green 488-labeled triamcinolone by subtenon injection using ocular fluorophotometry in rabbit eyes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18503001/),[ng] / [ml],84.68,222200,DB00620,Triamcinolone
,11084244,AUC,"AUC of the control, enhancer and i.v group were 2374+/-915, 3778+/-1721 and 3945+/-2085 h ng/ml, respectively, and the absolutive bioavailability of enhancer or i.v to control group were 159.14 or 332.35%, respectively.",Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084244/),[h·ng] / [ml],2374,227382,DB00620,Triamcinolone
,11084244,AUC,"AUC of the control, enhancer and i.v group were 2374+/-915, 3778+/-1721 and 3945+/-2085 h ng/ml, respectively, and the absolutive bioavailability of enhancer or i.v to control group were 159.14 or 332.35%, respectively.",Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084244/),[h·ng] / [ml],3778,227383,DB00620,Triamcinolone
,11084244,AUC,"AUC of the control, enhancer and i.v group were 2374+/-915, 3778+/-1721 and 3945+/-2085 h ng/ml, respectively, and the absolutive bioavailability of enhancer or i.v to control group were 159.14 or 332.35%, respectively.",Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084244/),[h·ng] / [ml],3945,227384,DB00620,Triamcinolone
,11084244,absolutive bioavailability,"AUC of the control, enhancer and i.v group were 2374+/-915, 3778+/-1721 and 3945+/-2085 h ng/ml, respectively, and the absolutive bioavailability of enhancer or i.v to control group were 159.14 or 332.35%, respectively.",Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084244/),%,159.14,227385,DB00620,Triamcinolone
,11084244,absolutive bioavailability,"AUC of the control, enhancer and i.v group were 2374+/-915, 3778+/-1721 and 3945+/-2085 h ng/ml, respectively, and the absolutive bioavailability of enhancer or i.v to control group were 159.14 or 332.35%, respectively.",Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084244/),%,332.35,227386,DB00620,Triamcinolone
,11084244,C(max),"The average C(max) of control and enhancer group were 263+/-159 and 362+/-201 ng/ml, and the mean T(max) of the control group and enhancer group were 5.00+/-1.67 and 4.33+/-0.82 h, respectively, but there was no significant difference.",Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084244/),[ng] / [ml],263,227387,DB00620,Triamcinolone
,11084244,C(max),"The average C(max) of control and enhancer group were 263+/-159 and 362+/-201 ng/ml, and the mean T(max) of the control group and enhancer group were 5.00+/-1.67 and 4.33+/-0.82 h, respectively, but there was no significant difference.",Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084244/),[ng] / [ml],362,227388,DB00620,Triamcinolone
,11084244,T(max),"The average C(max) of control and enhancer group were 263+/-159 and 362+/-201 ng/ml, and the mean T(max) of the control group and enhancer group were 5.00+/-1.67 and 4.33+/-0.82 h, respectively, but there was no significant difference.",Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084244/),h,5.00,227389,DB00620,Triamcinolone
,11084244,T(max),"The average C(max) of control and enhancer group were 263+/-159 and 362+/-201 ng/ml, and the mean T(max) of the control group and enhancer group were 5.00+/-1.67 and 4.33+/-0.82 h, respectively, but there was no significant difference.",Enhanced bioavailability by buccal administration of triamcinolone acetonide from the bioadhesive gels in rabbits. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084244/),h,4.33,227390,DB00620,Triamcinolone
,34350546,AUC0-last,"Systemic exposure following TAcs was approximately 1.5-fold higher than that following TA-ER injection (geometric mean [GM] AUC0-last 873,543 vs 557,602 h × pg/mL).","Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350546/),[h·pg] / [ml],"873,543",232825,DB00620,Triamcinolone
,34350546,AUC0-last,"Systemic exposure following TAcs was approximately 1.5-fold higher than that following TA-ER injection (geometric mean [GM] AUC0-last 873,543 vs 557,602 h × pg/mL).","Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350546/),[h·pg] / [ml],"557,602",232826,DB00620,Triamcinolone
,34350546,Cmax,GM Cmax was also higher in TAcs- than TA-ER-treated patients (2034 vs 1283 pg/mL).,"Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350546/),[pg] / [ml],2034,232827,DB00620,Triamcinolone
,34350546,Cmax,GM Cmax was also higher in TAcs- than TA-ER-treated patients (2034 vs 1283 pg/mL).,"Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34350546/),[pg] / [ml],1283,232828,DB00620,Triamcinolone
,20537996,elimination half-lives,"The elimination half-lives of TAP in the eye after intravitreal and subconjunctival injections were 8 and 0.5 h in vivo and 17 and 6.0 h postmortem, respectively.",Ocular pharmacokinetic study of a corticosteroid by 19F MR. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20537996/),h,8,239479,DB00620,Triamcinolone
,20537996,elimination half-lives,"The elimination half-lives of TAP in the eye after intravitreal and subconjunctival injections were 8 and 0.5 h in vivo and 17 and 6.0 h postmortem, respectively.",Ocular pharmacokinetic study of a corticosteroid by 19F MR. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20537996/),h,0.5,239480,DB00620,Triamcinolone
,20537996,elimination half-lives,"The elimination half-lives of TAP in the eye after intravitreal and subconjunctival injections were 8 and 0.5 h in vivo and 17 and 6.0 h postmortem, respectively.",Ocular pharmacokinetic study of a corticosteroid by 19F MR. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20537996/),h,17,239481,DB00620,Triamcinolone
,20537996,elimination half-lives,"The elimination half-lives of TAP in the eye after intravitreal and subconjunctival injections were 8 and 0.5 h in vivo and 17 and 6.0 h postmortem, respectively.",Ocular pharmacokinetic study of a corticosteroid by 19F MR. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20537996/),h,6.0,239482,DB00620,Triamcinolone
,20537996,half-lives associated,The half-lives associated with clearance were 14 h for intravitreal injection and 0.5 h for subconjunctival injection.,Ocular pharmacokinetic study of a corticosteroid by 19F MR. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20537996/),h,14,239483,DB00620,Triamcinolone
,20537996,half-lives associated,The half-lives associated with clearance were 14 h for intravitreal injection and 0.5 h for subconjunctival injection.,Ocular pharmacokinetic study of a corticosteroid by 19F MR. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20537996/),h,0.5,239484,DB00620,Triamcinolone
,3485989,steady state plasma concentration,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[mg] / [l],90.9,239639,DB00620,Triamcinolone
,3485989,steady state plasma concentration,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[mg] / [l],64.7,239640,DB00620,Triamcinolone
,3485989,clearance,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),[ml] / [min],87.3,239641,DB00620,Triamcinolone
,3485989,clearance,"The mean steady state plasma concentration (+/- s.e. mean) of salicylate decreased significantly after intra-articular steroid (90.9 +/- 14.8 mg l-1-64.7 +/- 8.9, P less than 0.05), whilst the mean clearance increased significantly (87.3 +/- 20.6 ml min-1-120.6 +/- 28.3, P less than 0.05).",The effect of intra-articular steroids on plasma salicylate concentrations. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3485989/),,120.6,239642,DB00620,Triamcinolone
,3369245,lag-time,72.9% of the oral dose was absorbed with an average lag-time of 2.2 h.,[Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369245/),h,2.2,248942,DB00620,Triamcinolone
,3369245,Peak plasma concentrations,"Peak plasma concentrations amounted to 2.9 micrograms/ml after 3.1 h, as compared to 2.15 micrograms/ml, 20-30 min following an intramuscular injection of 75 mg.",[Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369245/),[μg] / [ml],2.9,248943,DB00620,Triamcinolone
,3369245,Peak plasma concentrations,"Peak plasma concentrations amounted to 2.9 micrograms/ml after 3.1 h, as compared to 2.15 micrograms/ml, 20-30 min following an intramuscular injection of 75 mg.",[Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369245/),[μg] / [ml],2.15,248944,DB00620,Triamcinolone
,3369245,half-life,Diclofenac sodium was excreted with an average half-life of 1.15 h.,[Pharmacokinetics and biological availability of diclofenac preparations following intramuscular injection of 75 mg and oral administration of 150 mg of active drug]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3369245/),h,1.15,248945,DB00620,Triamcinolone
,20447969,half-life,The half-life of TA was 10.4 days in RPE/choroid.,Characterisation of systemic and ocular drug level of triamcinolone acetonide following a single sub-Tenon injection. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20447969/),d,10.4,257246,DB00620,Triamcinolone
,11107002,half-life of the rapid,The half-life of the rapid elimination phase was 83.5 min and of the slower phase was 12 h.,Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107002/),min,83.5,257972,DB00620,Triamcinolone
,11107002,half-life of the rapid,The half-life of the rapid elimination phase was 83.5 min and of the slower phase was 12 h.,Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107002/),h,12,257973,DB00620,Triamcinolone
,11107002,(,The term (Vss/Vc)-1was 12.3 indicating extensive distribution into the tissues.,Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107002/),,12.3,257974,DB00620,Triamcinolone
,11107002,Vss/Vc),The term (Vss/Vc)-1was 12.3 indicating extensive distribution into the tissues.,Pharmacokinetics and metabolic effects of triamcinolone acetonide and their possible relationships to glucocorticoid-induced laminitis in horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11107002/),,12.3,257975,DB00620,Triamcinolone
below,25700623,peak TA concentration,"Following a 50μL suprachoroidal injection, peak TA concentration in the aqueous was below 1ng/mL.",Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700623/),[ng] / [ml],1,264144,DB00620,Triamcinolone
,25700623,Maximum TA,Maximum TA in plasma was 11.6ng/mL.,Safety and pharmacodynamics of suprachoroidal injection of triamcinolone acetonide as a controlled ocular drug release model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25700623/),[ng] / [ml],11.6,264145,DB00620,Triamcinolone
,6958498,plasma half-life,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),h,2.8,266547,DB00620,Triamcinolone
,6958498,distribution volume,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),1,301.3,266548,DB00620,Triamcinolone
,6958498,plasma clearance,"The plasma half-life was 2.8 +/- 1.1 h (mean +/- SD), distribution volume 301.3 +/ 41.7 1 and plasma clearance 83.7 +/- 27.5 1/h.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),[1] / [h],83.7,266549,DB00620,Triamcinolone
,6958498,systemic availability,"The systemic availability was 10.7 +/- 4.3% after oral administration and 72.8 +/- 42.0% after inhalation, corrected for the amounts of substance deposited in the inhalation device and oral cavity.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),%,10.7,266550,DB00620,Triamcinolone
,6958498,systemic availability,"The systemic availability was 10.7 +/- 4.3% after oral administration and 72.8 +/- 42.0% after inhalation, corrected for the amounts of substance deposited in the inhalation device and oral cavity.","Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6958498/),%,72.8,266551,DB00620,Triamcinolone
,21071288,flow rate,Extracts were centrifuged and chromatographic separation was achieved using a Zorbax Eclipse Plus C18 column using gradient elution with a mobile phase of acetonitrile and water with formic acid at a flow rate of 0.2ml/min.,Dexamethasone quantification in dried blood spot samples using LC-MS: The potential for application to neonatal pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21071288/),[ml] / [min],0.2,271581,DB00620,Triamcinolone
,21071288,m/z,LC-MS detection was conducted with single ion monitoring using target ions at m/z 393.1 for dexamethasone and 435.1 for the internal standard.,Dexamethasone quantification in dried blood spot samples using LC-MS: The potential for application to neonatal pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21071288/),,393.1,271582,DB00620,Triamcinolone
,21071288,m/z,LC-MS detection was conducted with single ion monitoring using target ions at m/z 393.1 for dexamethasone and 435.1 for the internal standard.,Dexamethasone quantification in dried blood spot samples using LC-MS: The potential for application to neonatal pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21071288/),,435.1,271583,DB00620,Triamcinolone
,21071288,overall extraction recovery,The overall extraction recovery of dexamethasone from DBS samples was 99.3% (94.3-105.7%).,Dexamethasone quantification in dried blood spot samples using LC-MS: The potential for application to neonatal pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21071288/),%,99.3,271584,DB00620,Triamcinolone
